IL262143A - Improvements in cancer treatment - Google Patents

Improvements in cancer treatment

Info

Publication number
IL262143A
IL262143A IL262143A IL26214318A IL262143A IL 262143 A IL262143 A IL 262143A IL 262143 A IL262143 A IL 262143A IL 26214318 A IL26214318 A IL 26214318A IL 262143 A IL262143 A IL 262143A
Authority
IL
Israel
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
IL262143A
Other languages
English (en)
Hebrew (he)
Original Assignee
Noxopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxopharm Ltd filed Critical Noxopharm Ltd
Publication of IL262143A publication Critical patent/IL262143A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL262143A 2016-04-06 2018-10-04 Improvements in cancer treatment IL262143A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662318946P 2016-04-06 2016-04-06
PCT/AU2016/050674 WO2017173474A1 (en) 2016-04-06 2016-07-28 Improvements in cancer treatment

Publications (1)

Publication Number Publication Date
IL262143A true IL262143A (en) 2018-11-29

Family

ID=60000141

Family Applications (1)

Application Number Title Priority Date Filing Date
IL262143A IL262143A (en) 2016-04-06 2018-10-04 Improvements in cancer treatment

Country Status (11)

Country Link
US (2) US20190160004A1 (enExample)
EP (2) EP3939583A1 (enExample)
JP (1) JP2019510830A (enExample)
KR (1) KR20190016017A (enExample)
CN (1) CN109475522A (enExample)
AU (2) AU2016401508B2 (enExample)
CA (1) CA3058479A1 (enExample)
IL (1) IL262143A (enExample)
RU (1) RU2018137897A (enExample)
SG (1) SG11201808777UA (enExample)
WO (1) WO2017173474A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513826A (ja) * 2016-04-06 2019-05-30 ノクソファーム リミティド 放射線療法の改善
CA3058503A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
JP2023519990A (ja) 2020-03-30 2023-05-15 ノクソファーム リミティド 感染に関連する炎症の治療のための方法
WO2022204757A1 (en) * 2021-03-30 2022-10-06 Noxopharm Limited Improved isoflavone formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
CN1681386B (zh) * 2002-07-24 2010-05-26 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其制备方法
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
JP2007525485A (ja) 2003-11-19 2007-09-06 ノボゲン リサーチ ピーティーワイ リミテッド 複合的な放射線治療及び化学治療の組成物及び方法
DE102005009515A1 (de) * 2005-02-25 2006-09-07 Exner, Heinrich, Dr. Verfahren zur Herstellung einer Zubereitung einer DMSO-haltigen festen Silikonölemulsion zur Bindung von reaktiven Sauerstoffverbindungen im Körper von Menschen und Tieren
EP1948103A2 (en) * 2005-09-15 2008-07-30 UMD, Inc. A method of intraepithelial and systemic exposure of therapeutic agents following vaginal and oral cavity administration
US20110166142A1 (en) * 2007-06-29 2011-07-07 Eleanor Eiffe 2-substituted isoflavonoid compounds, medicaments and uses
EP2334296A4 (en) * 2008-08-29 2012-04-25 Novogen Res Pty Ltd IMMUNOMODULATING ACTIVITIES
KR20110004525A (ko) * 2009-07-08 2011-01-14 동의대학교 산학협력단 제니스테인과 ｔｒａｉｌ을 포함하는 간암 치료용 조성물

Also Published As

Publication number Publication date
RU2018137897A3 (enExample) 2020-05-13
EP3439651A4 (en) 2019-10-30
SG11201808777UA (en) 2018-11-29
AU2020204172A1 (en) 2020-07-09
RU2018137897A (ru) 2020-05-13
WO2017173474A1 (en) 2017-10-12
EP3939583A1 (en) 2022-01-19
CN109475522A (zh) 2019-03-15
KR20190016017A (ko) 2019-02-15
AU2016401508A1 (en) 2018-11-01
AU2016401508B2 (en) 2020-03-26
JP2019510830A (ja) 2019-04-18
EP3439651A1 (en) 2019-02-13
CA3058479A1 (en) 2017-10-12
US20190160004A1 (en) 2019-05-30
US20210338576A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
IL267158B (en) Amino-triazopyridine compounds and their use in cancer treatment
ZA201803742B (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
IL263123A (en) Cancer treatments
IL251630A0 (en) Combined therapy for use in cancer treatment
PL3197456T3 (pl) Leczenie nowotworów
PT3576740T (pt) Tratamento de cancro
SG10202105110VA (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
IL251903B (en) Epilimod for use in the treatment of colon cancer
IL247859A0 (en) Cancer treatment
ZA201707024B (en) Cancer treatment composition
IL262143A (en) Improvements in cancer treatment
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL274626A (en) Cancer treatment
GB201409363D0 (en) Skin cancer treatment
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
IL260814A (en) Cancer treatment
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
GB201707864D0 (en) Platinum-reistant cancer treatment
GB201522433D0 (en) Cancer treatment
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
GB201713852D0 (en) Cancer treatment
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201601248D0 (en) Cancer therapy